Tumor Biology

, Volume 35, Issue 6, pp 5487–5491 | Cite as

A systematic review of matrix metalloproteinase 9 as a biomarker of survival in patients with osteosarcoma

  • Hui Li
  • Kun Zhang
  • Li-hong Liu
  • Yurong Ouyang
  • Jie Bu
  • Hong-bin Guo
  • Tao Xiao
Research Article


Matrix metalloproteinase 9 (MMP-9) plays an important role in the progression of several types of cancer by increasing tumor growth, migration, invasion, and metastasis and is associated with poor disease prognosis. The possible prognostic value of MMP-9 in osteosarcoma has also been examined, but due to inconsistent results between studies, it has not been possible to draw firm conclusions. To clarify this issue, we conducted a meta-analysis of published studies to provide a comprehensive evaluation of the effect of high MMP-9 expression on the survival outcomes of osteosarcoma patients. Seven studies with a total of 339 patients with osteosarcoma were examined. The pooled odds ratio (OR) with corresponding 95 % confidence interval (95 % CI) was calculated to evaluate the effect of MMP-9 expression on overall survival. Meta-analysis showed that patients with high MMP-9 expression were significantly associated with lower overall survival when compared to their counterparts with low or undetectable MMP-9 expression (OR = 6.13, 95 % CI 3.45–10.89, P < 0.001). Sensitivity analysis suggested the pooled OR was stable and not significantly changed when a single study was removed. The results from the systematic review and meta-analysis show that MMP-9 is an effective biomarker for predicting survival of patients with osteosarcoma.


Matrix metalloproteinase 9 Osteosarcoma Prognosis Meta-analysis 



This work was supported by grants from the National Natural Science Foundation of China (no. 81372871) and Hunan Provincial Innovation Foundation For Postgraduate (no. CX2012B096).

Conflicts of interest



  1. 1.
    Geller DS, Gorlick R. Osteosarcoma: a review of diagnosis, management, and treatment strategies. Clin Adv Hematol Oncol H O. 2010;8(10):705–18.PubMedGoogle Scholar
  2. 2.
    Kobayashi E, Hornicek FJ, Duan Z. MicroRNA involvement in osteosarcoma. Sarcoma. 2012;2012:359739.PubMedCentralCrossRefPubMedGoogle Scholar
  3. 3.
    Hameed M, Dorfman H. Primary malignant bone tumors—recent developments. Semin Diagn Pathol. 2011;28(1):86–101.CrossRefPubMedGoogle Scholar
  4. 4.
    Weeden S, Grimer RJ, Cannon SR, Taminiau AH, Uscinska BM. The effect of local recurrence on survival in resected osteosarcoma. Eur J Cancer (Oxford, England: 1990). 2001;37(1):39–46.CrossRefGoogle Scholar
  5. 5.
    Harting MT, Blakely ML, Jaffe N, Cox Jr CS, Hayes-Jordan A, Benjamin RS, et al. Long-term survival after aggressive resection of pulmonary metastases among children and adolescents with osteosarcoma. J Pediatr Surg. 2006;41(1):194–9.CrossRefPubMedGoogle Scholar
  6. 6.
    Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res. 2006;69(3):562–73.CrossRefPubMedGoogle Scholar
  7. 7.
    Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2002;2(3):161–74.CrossRefPubMedGoogle Scholar
  8. 8.
    Viros D, Camacho M, Zarraonandia I, Garcia J, Quer M, Vila L, et al. Prognostic role of MMP-9 expression in head and neck carcinoma patients treated with radiotherapy or chemoradiotherapy. Oral Oncol. 2013;49(4):322–5.CrossRefPubMedGoogle Scholar
  9. 9.
    Vilen ST, Salo T, Sorsa T, Nyberg P. Fluctuating roles of matrix metalloproteinase-9 in oral squamous cell carcinoma. Sci World J. 2013;2013:920595.CrossRefGoogle Scholar
  10. 10.
    Gao XH, Yang XQ, Wang BC, Liu SP, Wang FB. Overexpression of twist and matrix metalloproteinase-9 with metastasis and prognosis in gastric cancer. APJCP. 2013;14(9):5055–60.PubMedGoogle Scholar
  11. 11.
    Huang Y, Wang JP. Expressions of MDM2 and MMP-9 in osteosarcoma tissue and clinical significances [article in Chinese]. J Pract Oncol. 2009;23(1):35–7.Google Scholar
  12. 12.
    Chen L, Lin JH, Zhang S. Expression of MMP-9 and TIMP-1 and their clinical significance in osteosarcoma [article in Chinese]. Chin J Exp Surg. 2004;21(12):1522–3.Google Scholar
  13. 13.
    Luo XZ, Ni JD. Expression and clinical significance of MMP-9 and PCNA in osteosarcoma [article in Chinese]. J Clin Res. 2006;23(5):682–4.Google Scholar
  14. 14.
    Li WX, Ye ZM, Yang DS, Tao HM. The expression of vascular endothelial growth factor, matrix metalloproteinases 2, 9 in osteosarcoma [article in Chinese]. Zhejiang Med J. 2006;28(9):691–4.Google Scholar
  15. 15.
    Foukas AF, Deshmukh NS, Grimer RJ, Mangham DC, Mangos EG, Taylor S. Stage-IIB osteosarcomas around the knee. A study of MMP-9 in surviving tumour cells. J Bone Joint Surg Br Vol. 2002;84(5):706–11.Google Scholar
  16. 16.
    Kushlinsky NE, Solovyov YN, Babkina IV, Gershtein ES, Bulicheva IV. Matrix metalloproteinases 2, 7, 9 and tissue inhibitor of matrix metalloproteinase-1 in the sera of patients with bone tumors. Bull Exp Biol Med. 2010;149(2):233–5.CrossRefPubMedGoogle Scholar
  17. 17.
    Uchibori M, Nishida Y, Nagasaka T, Yamada Y, Nakanishi K, Ishiguro N. Increased expression of membrane-type matrix metalloproteinase-1 is correlated with poor prognosis in patients with osteosarcoma. Int J Oncol. 2006;28(1):33–42.PubMedGoogle Scholar
  18. 18.
    Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ (Clin Res ed). 2003;327(7414):557–60.CrossRefGoogle Scholar
  19. 19.
    Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22(4):719–48.PubMedGoogle Scholar
  20. 20.
    DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–88.CrossRefPubMedGoogle Scholar
  21. 21.
    Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ (Clin Res ed). 1997;315(7109):629–34.CrossRefGoogle Scholar
  22. 22.
    Jaffe N. Osteosarcoma: review of the past, impact on the future. The American experience. Cancer Treat Res. 2009;152:239–62.CrossRefPubMedGoogle Scholar
  23. 23.
    Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, Shafie S. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature. 1980;284(5751):67–8.CrossRefPubMedGoogle Scholar
  24. 24.
    Stetler-Stevenson WG. Type IV, collagenases in tumor invasion and metastasis. Cancer Metastasis Rev. 1990;9(4):289–303.CrossRefPubMedGoogle Scholar
  25. 25.
    Zhang Q-W, Liu L, Chen R, Wei Y-Q, Li P, Shi H-S, et al. Matrix metalloproteinase-9 as a prognostic factor in gastric cancer: a meta-analysis. Asian Pac J Cancer Prev. 2012;13(6):2903–8.CrossRefPubMedGoogle Scholar
  26. 26.
    Song J, Su H, Zhou Y-Y, Guo L-L. Prognostic value of matrix metalloproteinase 9 expression in breast cancer patients: a meta-analysis. Asian Pac J Cancer Prev. 2013;14(3):1615–21.CrossRefPubMedGoogle Scholar
  27. 27.
    Peng WJ, Zhang JQ, Wang BX, Pan HF, Lu MM, Wang J. Prognostic value of matrix metalloproteinase 9 expression in patients with non-small cell lung cancer. Clinica Chim Acta Int J Clin Chem. 2012;413(13-14):1121–6.CrossRefGoogle Scholar
  28. 28.
    Li CY, Yuan P, Lin SS, Song CF, Guan WY, Yuan L, et al. Matrix metalloproteinase 9 expression and prognosis in colorectal cancer: a meta-analysis. Tumour Biol J Int Soc Oncodevelopmental Biol Med. 2013;34(2):735–41.CrossRefGoogle Scholar
  29. 29.
    Fu HL, Shao L, Wang Q, Jia T, Li M, Yang DP. A systematic review of p53 as a biomarker of survival in patients with osteosarcoma. Tumour Biol J Int Soc Oncodevelopmental Biol Med. 2013;34(6):3817–21.Google Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Hui Li
    • 1
  • Kun Zhang
    • 1
  • Li-hong Liu
    • 1
  • Yurong Ouyang
    • 1
  • Jie Bu
    • 1
  • Hong-bin Guo
    • 1
  • Tao Xiao
    • 1
  1. 1.Department of OrthopedicsThe Second Xiangya Hospital of Central South UniversityChangshaChina

Personalised recommendations